Gubra A S (GUBRF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the conference call. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key five on their telephone keypad. Now I will hand the conference over to the speakers. Please go ahead. Good morning. Welcome to the Huber investor presentation. My name is Markus Rohrwild, I am the CEO of Gubra. I'm joined here by our chief financial officer, Christian, our chief scientific officer, Luise, our chief medical and development officer, Thomas, the head of Gubra Ventures, Zoe, and the head of the Gubra COO, Trine. I will present an overview about the company and then we will move into the individual units. Just as a reminder, GUPRA is a disease agnostic tech biocompany, and we have deep expertise in peptide therapeutics and preclinical research services. Starting 2006, we will operate in three independent but synergistic business units. First, our GUPRA biotech unit, where we discover and develop peptide therapeutics to clinical proof of concept. our key value driver. Second, the GUPA CRO, where we deliver high quality preclinical research services to external customers, but also to our internal units, biotech units and ventures. And our new business unit, GUPA Ventures, where we incubate high value assets adjacent to our core therapeutic areas to create and accelerate additional value, all based in our commitment to society in Gubra Green, partially served by our ESG initiatives, but also we are investing 10% of our pre-tax profits into green initiatives. 2025 was a record year for Gubra, record revenue of $400 million. record operating profit of 325 million. Currently our advanced pipeline is in obesity, but we will also move beyond me...